FDA Grants Accelerated Approval to Otarmeni Gene Therapy for OTOF-Related Hearing Loss

In a pivotal trial, 42% of participants achieved normal hearing using the gene therapy indicated for pediatric and adult patients with severe-to-profound hearing loss due to biallelic OTOF gene variants. The US Food and Drug Administration (FDA) has granted accelerated approval for Otarmeni (lunsotogene parvec-cwha), a gene therapy for pediatric and adult patients with severe-to-profound and profound sensorineural...

Audiologists should be aware that Otarmeni is now FDA-approved for OTOF-related hearing loss and begin familiarizing themselves with candidate identification (genetic testing referral pathways) and post-treatment audiological monitoring protocols, though prescribing authority rests with physicians.

This is the first FDA-approved gene therapy for a genetic form of hearing loss, representing a paradigm shift away from device-based rehabilitation toward biological restoration for eligible patients.

1. 01FDA granted accelerated approval to Otarmeni for biallelic OTOF gene variant-related severe-to-profound hearing loss.
2. 02Approval covers both pediatric and adult patients.
3. 0342% of trial participants achieved normal hearing following treatment.
4. 04Accelerated approval means confirmatory trial data will still be required post-approval.
5. 05OTOF-related hearing loss is a specific genetic subtype; genetic testing is required to identify eligible patients.